苏巴伊特拉科纳 (SUBA-itraconazole) 用于治疗全身真菌感染
Jennifer Liu1, Kees A Vanderwyk1, Monica A Donnelley1
1Department of Pharmacy, UC-Davis Medical Center, Sacramento, CA 95816, USA.
Future microbiology
|July 16, 2024
概括
超生物可用的伊特拉科纳 (SUBA-ITZ) 与传统的伊特拉科纳 (c-ITZ) 相比,提供了更好的吸收和一致的药物水平. 这种新型配方允许更低的剂量,并已被批准用于治疗严重的真菌感染,如乳头菌.
科学领域:
- 药理学和药物输送 药理学和药物输送
- 菌类学和传染病的研究
背景情况:
- 传统的伊特拉科纳 (c-ITZ) 呈现出可变的口服吸收,限制了其在真菌感染中的治疗效果.
- 与c-ITZ相关的药物吸收问题需要对患者进行仔细监测,并可能导致治疗结果不佳.
研究的目的:
- 引入和评估超生物可用伊特拉科纳 (SUBA-ITZ),一种新型配方,旨在克服c-ITZ的吸收限制.
- 突出SUBA-ITZ在治疗特定真菌感染中的药理学优势和临床应用.
主要方法:
- SUBA-ITZ使用聚合物矩阵来增强药物的溶解和吸收.
- 该配方的pH驱动矩阵允许与质子抑制剂同时使用,而不会影响药物度.
- 在SUBA-ITZ和c-ITZ之间进行了比较性药理动力学分析.
主要成果:
- SUBA-ITZ表现出增强的生物可用性,使较低的剂量方案,同时达到可比的血清度c-ITZ.
- SUBA-ITZ是美国FDA批准的用于治疗芽细胞菌,细胞质菌和阿斯伯吉洛症的药物.
- SUBA-ITZ常见的不良影响包括胃肠道问题,外周,高血压.
结论:
- SUBA-ITZ代表了伊特拉科纳输送的重大进步,提供了改善的药理动力学特征和治疗一致性.
- 由于不同的药理学特性,SUBA-ITZ和c-ITZ是不可互换的,在配方过渡期间需要仔细考虑以防止药物错误.
关键词:
亚斯伯吉洛症 (Aspergillosis) 是一种疾病.这就是SUBA-伊特拉可纳.胚芽细胞结核病的发生基因质子体的发生 histoplasmosis.基-伊特拉科纳醇是一种这是伊特拉可纳.更多相关视频
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
127
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
127
01:29Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
01:21Drugs for Treatment of Constipation-Predominant IBS
152
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
152
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
113
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
113